GLP-1 drugs linked to lower kidney failure risk in bipolar disorder patients, Mayo Clinic study finds
Mayo Clinic researchers found that GLP-1 receptor agonists were associated with a lower risk of dialysis or kidney transplantation in adults with bipolar disorder and chronic kidney disease. The medications, widely used for diabetes and weight management, showed potential kidney-protective benefits in this patient population.
